Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome

Ann Intern Med. 2011 Sep 6;155(5):341-3. doi: 10.7326/0003-4819-155-5-201109060-00026.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Churg-Strauss Syndrome / drug therapy*
  • Churg-Strauss Syndrome / immunology
  • Down-Regulation
  • Drug Therapy, Combination
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunologic Factors / therapeutic use*
  • Immunosuppressive Agents / therapeutic use
  • Interleukin-5 / immunology*
  • Methotrexate / therapeutic use
  • Remission Induction

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Immunologic Factors
  • Immunosuppressive Agents
  • Interleukin-5
  • mepolizumab
  • Methotrexate